Charles Schwab’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Charles Schwab’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-4,880	Closed	-$52K	–	3184
2016 Q1	$52K	Sell	4,880 -75,035	-94%	-$1.49M	﹤0.01%	3028
2015 Q4	$2.36M	Hold	79,915	–	–	﹤0.01%	1996
2015 Q3	$2.53M	Buy	79,915 +9,310	+13%	+$445K	﹤0.01%	1931
2015 Q2	$4.18M	Buy	70,605 +46,991	+199%	+$3.31M	0.01%	1653
2015 Q1	$2.52M	Buy	23,614 +18,734	+384%	+$1.79M	﹤0.01%	1927
2014 Q4	$459K	Hold	4,880	–	–	﹤0.01%	2653
2014 Q3	$375K	Hold	4,880	–	–	﹤0.01%	2694
2014 Q2	$439K	Buy	4,880 +1,170	+32%	+$71.7K	﹤0.01%	2680
2014 Q1	$199K	Hold	3,710	–	–	﹤0.01%	2945
2013 Q4	$94K	Hold	3,710	–	–	﹤0.01%	3061
2013 Q3	$98K	Sell	3,710 -731	-16%	-$23.5K	﹤0.01%	3035
2013 Q2	$166K	Buy	+4,441	New	+$166K	﹤0.01%	2971

Other funds holding PTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Charles Schwab's PTX Position: Q2 2016 in Review

Charles Schwab sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2016, closing a stake of 4,880 shares — an estimated $52K sold.

Charles Schwab first reported a position in PTX in Q2 2013 and held it in 12 quarters. The position peaked at $4.18M in Q2 2015. 56 funds tracked by Wall St. Rank hold PTX as of Q2 2016.

Charles Schwab reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2016 after selling out during the quarter.
Charles Schwab sold 4,880 Pernix Therapeutics Holdings, Inc. shares in Q2 2016, an estimated $52K.
Charles Schwab first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2013 and held it in 12 quarters.
Charles Schwab's Pernix Therapeutics Holdings, Inc. position peaked at $4.18M in Q2 2015.
56 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2016.

Based on Charles Schwab's 13F filing for Q2 2016, filed 15 Aug 2016.